-
Depatux-M combined temequinathemide therapy EGFR amplification relapse GBM
Time of Update: 2020-05-31
Backgrounded Depatux-M is a tumor-specific antibody drug coupling consisting of activated epithelial growth factor receptor (EGFR) antibodies (ABT-806) and toxin monomethylauristatin-F Martin van den
-
Document review and Meta analysis of MRI identification of PCNSL and GBM
Time of Update: 2020-05-31
Clinically, it is important to accurately identify primary central nervous system lymphoma (primary central nervous system lymphoma, PCNSL) and glioblastoma (GBM) prior to surgery Because there is a b
-
Subtypes of different clinical characteristics of pineal mothericular tumor
Time of Update: 2020-05-31
Pineoblastoma (PB) is a rare childhood brain tumor derived from the pineal glands The survival rate of children is not high Bryan K Li, of the Department of Blood and Oncology at the University of Tor
-
YAP1 gene abnormality drives the occurrence of tube membrane tumor
Time of Update: 2020-05-31
Background ventricular membrane tumor (Ependymoma, EPN) is a central nervous system (CNS) neuroepithelieur tumor, accounting for 10% of all CNS malignancies; It occurs at all ages; Because EPN is a c
-
18F-FET PET scans identify GMB recurrence and therapeutic reactive changes
Time of Update: 2020-05-31
Background conventional MRI examination was not easy to distinguish between glioblastoma (GBM) recurrence and therapeutic reactive changes, because relapse and therapeutic reactive changes often occu
-
PD-L1/PD-1 axis in GBM
Time of Update: 2020-05-31
Polymorphic glioblastoma (GBM) is the most common primary central nervous system malignancies Currently, the standard treatment is the maximum surgical excision and combination of TMZ radiation chemot
-
Bevala-zons to treat non-small cell lung cancer with simultaneous brain metastasis
Time of Update: 2020-05-31
Background Bevacizumab,BEV) is a targeted drug for vascular epidermal growth factor A (VEGF-A) Clinical studies have shown that BEV can improve the progression-free survival of glioblastoma patients,
-
Serum infrared spectroscopy to identify gliomas and lymphomas
Time of Update: 2020-05-31
In the UK, more than a third of patients with brain tumours have seen a GP more than five times before diagnosis, and 62 per cent have been admitted to hospital during an emergency episode There is no
-
Advances in the diagnosis and treatment of glioblastoma
Time of Update: 2020-05-31
Background glioblastoma (GBM) is a common malignant brain tumor, accounting for 45% of central nervous system malignancies; The GBM prognosis is poor Nancy Ann Oberheim Bush of the Neurosurgery Group
-
Oncology treatment electric field combined with lomoxin and tamoxetine to treat newly diagnosed glioblastoma
Time of Update: 2020-05-31
In the ef-14 trial for the newly diagnosed glioblastoma (ndGBM), TMZ therapy with tTFields significantly improved the overall survival rate of patients In the NOA-09/CeTeG trial, the combination of O6
-
5-Azathin therapeutic effect on IDH1/2 mutant glioma
Time of Update: 2020-05-30
About 40% of gliomas have mutations in the isocitric acid dehydrogenase gene (IDH1 or IDH2) Idh1/2 mutant glioma has a better prognosis IDH1/2 mutant gliomas typically exhibit extensive DNA hypermethy
-
Adults withon-screen brain tumor sacliver surgery do not require regular icU
Time of Update: 2020-05-30
Patients with open craniofacial surgery are routinely admitted to the Neurosurgery Intensive Care Unit (ICU) or sub-intensive care unit (medium care unit, MCU) for the first 12-24 hours after surgery
-
Nature!' Surprise discovery! Also a cancer metastasis! Lymph node metastasis and far-end metastasis are very different!
Time of Update: 2020-05-30
May 27, 2020 / bioON/bioON/--the potential evolutionary process of metastasis -- the development of secondary malignant tumor from primary tumors -- is still not entirely clear in human patients
-
PNAS breakthrough: Antimalarial drugs promise to treat deadly brain cancer!
Time of Update: 2020-05-30
May 28 , 2020 /PRNewswire BIOON/-GBM, a polymorphic glioblastoma is an invasive brain cancer, often fatal But the new findings by researchers at Virginia State University's Massey Cancer Center (VCU
-
Target NGS panel for clinical detection of somatic cell mutations of gliomas
Time of Update: 2020-05-30
In clinical practice, the target-generation second-generation sequencing plate (next-generation sequencing panel, NGS panel) for solid tumors has been widely used for the precise diagnosis of tumors a
-
Micro-evolution trajectory of glioma recurrence
Time of Update: 2020-05-30
Diffuse glioma is the most common malignant brain tumor in adults, and it is still inevitable to relapse after surgical removal and chemotherapy Molecular diagnosis of gliomas has been widely used, bu
-
High-throughput drug screening seeks treatment for diffuse midline glioma
Time of Update: 2020-05-30
Diffuse midline glioma (diffuse midline gliomas, DMG) is a type of malignant tumor that occurs in children and the central nervous system, including the thalamus, bridge brain, and spinal cord The sig
-
Resting fMRI detects full-brain function connection impairment in glioma patients
Time of Update: 2020-05-30
Glioma is a disease that affects the whole brain, and the spread of tumor cells extends far beyond the visible lesions At present, neuroradiology imaging can only show the subject of the tumor and its
-
The world's first BCMA targeted therapy! GSK announces new data from the Belantamab mafodotin myeloma project: 78% of the total remission rate for early treatment!
Time of Update: 2020-05-30
May 29, 2020 / Biovalley BIOON/ -- GlaxoSmithKline (GSK) recently released the latest data on the DREAMM clinical program, further highlighting the potential of belantamab mafodotin (GSK2857916)
-
Molecular mechanism of tumor electric field therapy
Time of Update: 2020-05-30
Tumor electric field therapy (tumor field fields, TTFields) is a non-invasive physical model for tumor therapy, low-intensity, medium-frequency AC electric field in the induced DNA double-stranded fra
